JP2018507689A5 - - Google Patents

Download PDF

Info

Publication number
JP2018507689A5
JP2018507689A5 JP2017542470A JP2017542470A JP2018507689A5 JP 2018507689 A5 JP2018507689 A5 JP 2018507689A5 JP 2017542470 A JP2017542470 A JP 2017542470A JP 2017542470 A JP2017542470 A JP 2017542470A JP 2018507689 A5 JP2018507689 A5 JP 2018507689A5
Authority
JP
Japan
Prior art keywords
peptide
xaa
linker
seq
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017542470A
Other languages
English (en)
Japanese (ja)
Other versions
JP7028643B2 (ja
JP2018507689A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SG2016/050079 external-priority patent/WO2016130092A1/en
Publication of JP2018507689A publication Critical patent/JP2018507689A/ja
Publication of JP2018507689A5 publication Critical patent/JP2018507689A5/ja
Application granted granted Critical
Publication of JP7028643B2 publication Critical patent/JP7028643B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017542470A 2015-02-13 2016-02-15 膜を破壊しないp53活性化ステープルペプチド Active JP7028643B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201501119W 2015-02-13
SG10201501119W 2015-02-13
PCT/SG2016/050079 WO2016130092A1 (en) 2015-02-13 2016-02-15 Non-membrane disruptive p53 activating stapled peptides

Publications (3)

Publication Number Publication Date
JP2018507689A JP2018507689A (ja) 2018-03-22
JP2018507689A5 true JP2018507689A5 (enExample) 2019-03-28
JP7028643B2 JP7028643B2 (ja) 2022-03-02

Family

ID=56614951

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017542470A Active JP7028643B2 (ja) 2015-02-13 2016-02-15 膜を破壊しないp53活性化ステープルペプチド

Country Status (6)

Country Link
US (1) US11319344B2 (enExample)
EP (1) EP3256484B1 (enExample)
JP (1) JP7028643B2 (enExample)
CN (1) CN107531759B (enExample)
SG (1) SG11201706562QA (enExample)
WO (1) WO2016130092A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3838924A4 (en) * 2018-07-31 2022-06-22 Lemonex Inc. POLYPEPTIDE DELIVERY COMPOSITION
WO2020027585A2 (ko) * 2018-07-31 2020-02-06 주식회사 레모넥스 폴리펩타이드 전달용 조성물
CN115052614B (zh) * 2019-12-05 2025-10-21 亚洲大学校产学协力团 包含肽或其混合物作为活性成分的用于预防或治疗白塞氏病和类风湿性关节炎的药物组合物
CN111613275B (zh) * 2020-05-26 2021-03-16 中国海洋大学 一种基于rmsd多特征的药物分子动力学结果分析方法
IT202000016807A1 (it) * 2020-07-10 2022-01-10 Humanitas Mirasole Spa Peptidi associati a tumore e loro impiego
AU2021360898A1 (en) 2020-10-14 2023-03-23 Dana-Farber Cancer Institute, Inc. Chimeric conjugates for degradation of viral and host proteins and methods of use
WO2024051616A1 (zh) * 2022-09-09 2024-03-14 湖南大学 一种多肽及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009149339A2 (en) 2008-06-05 2009-12-10 University Of Maryland, Baltimore P53 activator peptides
PE20120630A1 (es) * 2009-08-17 2012-05-26 Roche Glycart Ag Inmunoconjugados dirigidos
US20120328692A1 (en) 2011-06-24 2012-12-27 University Of Maryland, Baltimore Potent d-peptide antagonists of mdm2 and mdmx for anticancer therapy
SG11201502584XA (en) 2012-10-01 2015-05-28 Agency Science Tech & Res Peptides and methods for treating cancer
KR20150131244A (ko) * 2013-03-13 2015-11-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스테이플드 및 스티치드 폴리펩티드 및 그의 용도
US20150010932A1 (en) * 2013-07-02 2015-01-08 Salk Institute For Biological Studies Methods for assaying protein-protein interactions

Similar Documents

Publication Publication Date Title
CN112585156A (zh) 用于结合psma的肽配体
EP2035041B1 (en) Conjugates for innate immunotherapy of cancer
Glaffig et al. A fully synthetic glycopeptide antitumor vaccine based on multiple antigen presentation on a hyperbranched polymer
CN112585158A (zh) 用于结合EphA2的肽配体
CN112533937A (zh) 用于结合cd38的肽配体
RU2013137868A (ru) Меченые альдегидом полипептиды иммуноглобулина и способы их применения
JP2020502051A5 (enExample)
CN104130315B (zh) 一种特异靶向her2蛋白的多肽
JP2015519339A5 (enExample)
CN112585155A (zh) 用于结合il-17的肽配体
CN107148425A (zh) 对mt1‑mmp特异性的双环肽配体
JP2014166186A5 (enExample)
EP4055037A1 (en) Il-2r beta gamma c binding compounds
AU2019272844B2 (en) Improved methods of manufacturing peptide-based vaccines
Pechar et al. The coiled coil motif in polymer drug delivery systems
KR20170085593A (ko) 세포 투과성 스테이플 펩타이드, 이의 제조방법 및 그 용도
US20250127887A1 (en) Self-Assembling Nanoparticles Based On Amphiphilic Peptides
JP2024508969A5 (enExample)
Hu et al. Targeted modification of the cationic anticancer peptide HPRP-A1 with iRGD to improve specificity, penetration, and tumor-tissue accumulation
WO2011071279A2 (ko) Bpb-기반 카르고 운반 시스템
CN105085631A (zh) 一种特异靶向her2蛋白的多肽及其应用
CN111971060A (zh) 募集抗体并靶向肿瘤细胞的双功能分子
CN105085632A (zh) 一种特异靶向egfr蛋白的多肽及其应用
JP2015512247A5 (enExample)
BR112012025567A2 (pt) peptídeos de cdca5 e vacinas que incluem os mesmos